spesolimab generalized pustular psoriasis
Selected indexed studies
- Trial of Spesolimab for Generalized Pustular Psoriasis. (N Engl J Med, 2021) [PMID:34936739]
- Spesolimab for the Treatment of Generalized Pustular Psoriasis. (Drugs, 2024) [PMID:38114719]
- Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval. (Front Immunol, 2024) [PMID:39104539]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Trial of Spesolimab for Generalized Pustular Psoriasis. (2021) pubmed
- Spesolimab for the Treatment of Generalized Pustular Psoriasis. (2024) pubmed
- Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval. (2024) pubmed
- Treatment with spesolimab in patients with generalized pustular psoriasis: a review of real-world experience. (2025) pubmed
- Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients. (2024) pubmed
- The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab. (2023) pubmed
- Generalized pustular psoriasis successfully treated with spesolimab: A case report. (2024) pubmed
- Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1. (2025) pubmed
- Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation. (2023) pubmed
- Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date. (2024) pubmed